Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
BPC-157 remains categorized strictly as an unapproved research compound reserved for laboratory evaluation
The research literature differs in shape: AOD-9604 research base centers on the Metabolic Pharmaceuticals development program plus mechanism research on lipolytic activity Tesamorelin research base spans GHRH analog pharmacology plus the FDA-approved pharmaceutical clinical literature Application Comparison The mechanisms translate to different research applications: AOD-9604 research applications: Lipolytic mechanism research Fat metabolism studies Receptor-independent GH biology research Research on isolated lipolytic activity without IGF-1 effects Tesamorelin research applications: GHRH receptor pharmacology Pituitary GH axis research Multi-system effects of endogenous GH release (IGF-1 effects, downstream signaling) DPP-4-resistant peptide modification research These are different research applications with minimal overlap
One injection once daily after breakfast
The reconstitution process is identical, but the math and practical considerations change in important ways
